CARGO Therapeutics

CARGO Therapeutics is focused on developing advanced cell therapies for cancer, with a primary mission to create more durable and effective treatments for patients who have relapsed or are refractory to existing CAR T-cell therapies. The company's core technology, the Switch technology, is designed to enhance CAR T-cell persistence and function while mitigating exhaustion. CARGO became a public company via an IPO in November 2023 and is advancing a pipeline of novel CAR T-cell candidates targeting hematological malignancies.

Proprietary cell engineering platform featuring 'Switch' technology designed to enhance CAR T-cell persistence, function, and resistance to exhaustion, enabling next-generation autologous cell therapies for cancer.

1 drug in pipeline

Total raised: $200M

CARGO faces competition from other CD22 CAR T programs, bispecific/dual-targeting CAR T approaches, allogeneic CAR T developers, and non-cell therapy modalities like bispecific antibodies. Its differentiation is its specific focus on the post-CD19 CAR T failure population and its proprietary Switch technology designed to enhance T-cell persistence and durability.